STOCK TITAN
  1. Home
  2. News
  3. FATE

Fate Therapeutics Inc - FATE STOCK NEWS

Welcome to our dedicated news page for Fate Therapeutics (Ticker: FATE), a resource for investors and traders seeking the latest updates and insights on Fate Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fate Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fate Therapeutics's position in the market.

News
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Fate Therapeutics, Inc. (NASDAQ: FATE) will present at the 23rd Annual Needham Virtual Healthcare Conference to discuss their iPSC-derived cellular immunotherapies for cancer and autoimmune disorders. The webcast will be available on the company's website for viewing after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
conferences
-
News
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Fate Therapeutics (FATE) granted 6,400 restricted stock units to a new non-executive employee. The RSUs will vest over four years, subject to continuous employment. The grant was approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
management
-
News
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
Rhea-AI Summary
Fate Therapeutics, Inc. announces the pricing of an underwritten offering of 14,545,454 shares of its common stock at $5.50 per share, along with a concurrent private placement of pre-funded warrants. The Company expects gross proceeds of approximately $100.0 million from the offerings, with participation from various institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
none
News
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Fate Therapeutics grants a non-qualified stock option to a newly-hired employee for 40,000 shares at $7.74 per share. The option vests over four years, aligning with Nasdaq regulations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.15%
Tags
management
-
News
Fate Therapeutics to Present at Upcoming March Investor Conferences
Rhea-AI Summary
Fate Therapeutics, Inc. announces participation in multiple investor conferences to discuss its pipeline of cellular immunotherapies for cancer and autoimmune disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.17%
Tags
conferences
-
News
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Rhea-AI Summary
Fate Therapeutics, Inc. reported strong business highlights and financial results for Q4 2023, including a CIRM grant for FT819 CAR T-cell program in lupus, initiation of FT522 and FT825 clinical studies, and a cash position of $316 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.34%
Tags
earnings
News
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Fate Therapeutics, Inc. to report its fourth quarter and full year 2023 financial results and provide a corporate update on February 26, 2024. The company focuses on iPSC-derived cellular immunotherapies for cancer and autoimmune disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
conferences earnings
-
News
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Fate Therapeutics, Inc. (FATE) granted restricted stock units (RSUs) representing 32,600 shares of its common stock to two newly-hired non-executive employees. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
Rhea-AI Summary
Fate Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: FATE), has initiated enrollment for its Phase 1 clinical trial of FT825 / ONO-8250, a multiplexed-engineered, chimeric antigen receptor (CAR) T-cell product candidate targeting human epidermal growth factor receptor 2 (HER2). The company's iPSC-derived CAR T-cell product candidate incorporates a novel HER2-targeted antigen binding domain and is designed to treat solid tumors. The Phase 1 study is being conducted in collaboration with Ono Pharmaceutical Co., Ltd.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.28%
Tags
clinical trial
News
Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO
Rhea-AI Summary
Radionetics Oncology, Inc. (RADN) completes $52.5 million Series A financing led by Frazier Life Sciences, 5AM Ventures, and DCVC Bio, bringing total raised to date to $82.5 million. Paul Grayson joins as CEO, bringing expertise in business strategy, oncology, and G-protein coupled receptor biology. Eric Shiozaki, Ph.D., Partner at DCVC Bio, appointed to the board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
management
Stock FATE logo
Fate Therapeutics Inc

Nasdaq:FATE

FATE Rankings

#2871 Ranked by Market Cap
#5480 Ranked by Stock Gains
N/A Ranked by Dividends

FATE Stock Data

656.53M
80.71M
1.47%
91.78%
14.49%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
San Diego

About FATE

fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade"​ ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.